MEDTRONIC HEART VALVES DIVISION MEDTRONIC TRANSCATHETER VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
|
Back to Search Results |
|
Model Number MDT-TRANS VALVE |
Device Problems
Gradient Increase (1270); Perivalvular Leak (1457); Inadequacy of Device Shape and/or Size (1583); Patient Device Interaction Problem (4001)
|
Patient Problems
Stroke/CVA (1770); Non specific EKG/ECG Changes (1817); Obstruction/Occlusion (2422); Heart Failure/Congestive Heart Failure (4446); Valvular Insufficiency/ Regurgitation (4449)
|
Event Date 03/11/2024 |
Event Type
Injury
|
Manufacturer Narrative
|
Citation: scotti a, sturla m, costa g, et al.Evolut pro and sapien ultra performance in small aortic annuli: the opera-tavi registry.Jacc cardiovasc interv.2024;17(5):681-692.Doi:10.1016/j.Jcin.2024.01.006 earliest date of publication used for date of event.Medtronic products referenced: evolut pro (product code npt, pma# p130021) and evolut pro+ (product code npt, pma# p130021).Earliest approved product used for product code and pma#.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product, no definitive conclusion can be made regarding the clinical observations.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Event Description
|
Literature was reviewed regarding a comparison of the medtronic evolut pro and pro+ (n = 251) and the non-medtronic sapien 3 ultra (n = 251) transcatheter aortic valve replacement (tavr) platforms in patients with small aortic annuli.In the evolut r/pro+ group, the authors observed a kaplan-meier estimated rate of 26 all-cause deaths within one year of tavr.No evidence was presented to suggest that a medtronic product or its function contributed to any of the deaths.Other adverse events that occurred in the evolut r/pro+ group were described as follows: need for valve recapturing/repositioning during procedure, two transcatheter valves implanted during procedure, coronary obstruction during procedure, stroke (disabling or non-disabling), permanent pacemaker implantation, hospitalization for heart failure, prosthesis-patient mismatch, residual mean gradient = 20 mm hg, and trace to moderate paravalvular leak (pvl).The authors stated that there were no cases of severe pvl in the overall study cohort.No further information was provided pertaining to medtronic products.
|
|
Search Alerts/Recalls
|
|
|